Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Femal patients age 18 or older at time of informed consent
• Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis)
• Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
• Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025
Locations
Other Locations
Germany
Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
RECRUITING
Erlangen
Contact Information
Primary
Sponsor's study office
studien@ifg-erlangen.de
+49 15739466438
Time Frame
Start Date: 2026-02-19
Estimated Completion Date: 2027-03
Participants
Target number of participants: 200
Treatments
High-risk HR+/HER2- early breast cancer patients
High-risk HR+/HER2- early breast cancer patients under abemaciclib therapy
Related Therapeutic Areas
Sponsors
Collaborators: Lilly Deutschland GmbH Germany, AGO-B Breast Study Group
Leads: Institut fuer Frauengesundheit